Wednesday, December 05, 2018 8:42:09 AM
I really don't understand your response to my very simple point. I've been in CTSO for 8+ years and I've accumulated a very large share count. I don't "trade" it because this type of stock can triple overnight. My point is that thinly traded, speculative biotechs like this absolutely do NOT trade based on classical technical parameters or even fundamentals. I was amused by the ridiculous chatter over the irrelevant "success fee" from a few months ago, much as I'm amused at the quarterly perseveration about sales data. What matters in this type of stock is the potential for massive success, and that's it. And yes, this can triple overnight. It can also go to zero overnight. I think the former is more likely at some point, perhaps sooner than you think. No chart or support level can predict a doubling or tripling overnight, but that's what happens when some of this massive potential is realized or becomes imminent in people's minds. If we were to see a partnership with one of the CAR-T cell pharma companies, I believe this would at least double and perhaps triple overnight or soon thereafter. No chart would be helpful in guiding to that determination. It's the odds of massive potential and a very low current market cap and NOT classical technical analysis that guides share price in these instances. Anything else, although perhaps well-intentioned, is superfluous noise and at least for me, irritating to wade through on a regular basis while looking for substantive posts. That's it.
Recent CTSO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:21:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:05:35 PM
- CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update • PR Newswire (US) • 05/13/2026 08:00:00 PM
- CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights • PR Newswire (US) • 04/30/2026 11:00:00 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/15/2026 09:18:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 11:00:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 11:04:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:27:51 PM
- CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/25/2026 08:05:00 PM
- CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 • PR Newswire (US) • 03/19/2026 01:44:00 PM
- CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/05/2026 12:00:00 PM
- CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update • PR Newswire (US) • 01/12/2026 12:00:00 PM
- CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 • PR Newswire (US) • 12/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 02:09:45 AM
- Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/17/2025 10:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:34:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:32:19 PM
- CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update • PR Newswire (US) • 11/13/2025 09:05:00 PM
- CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/11/2025 12:00:00 PM
- CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 10/30/2025 11:00:00 AM
- In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer • PR Newswire (US) • 10/28/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2025 08:20:54 PM
- CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen • PR Newswire (US) • 09/29/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2025 08:35:38 PM
- CytoSorbents Provides DrugSorb-ATR Regulatory Update • PR Newswire (US) • 09/16/2025 11:00:00 AM
